March 9, 1998
AMERIPATH, INC. ANNOUNCES NEW ACQUISITION

Riviera Beach, FL, March 9, 1998 - AmeriPath, Inc. (Nasdaq: PATH), a physician practice management company focused on anatomic pathology services, announced today that it has completed the acquisition of an anatomic pathology practice located in Texas. Terms of the transaction were not disclosed.

Rhonda R. Porterfield, M.D. is a hospital-based pathology practice located in Denton, Texas. It operates from Denton Community Hospital, which is based north of Dallas. This acquisition is the Company's third in the Texas market. Combining Dr. Porterfield with Freeman-Cockerell Laboratories and UniPath, AmeriPath's first two acquisitions in Texas, this brings the total number of AmeriPath anatomic pathologists in the Dallas metropolitan area to 25.

"Dr. Porterfield has built an outstanding reputation for her practice in the 10 years she has worked in the Dallas market, and we are proud to add Dr. Porterfield's practice to the AmeriPath team," said Jim New, President and CEO of AmeriPath, Inc. "This acquisition will benefit from the synergies and economies of scale as it joins with our existing practices in Dallas while providing another component for our strategic plan to establish a regional business model in Texas. Dallas continues to be a key geographic marketplace for AmeriPath, and we believe this acquisition will add momentum to our growth opportunities there."

AmeriPath, Inc. is the nation's leading physician practice management company focused on providing anatomic pathology services to physicians, hospitals, national clinical laboratories and managed care organizations. The company presently operates in eight states and provides medical services through outpatient pathology laboratories, hospital inpatient laboratories and outpatient surgery centers.

...................................................................................................................

This release contains certain forward-looking statements regarding AmeriPath, including its operations and prospects. Past performance is not necessarily indicative of future results. In addition, AmeriPath's actual results could differ materially from the results anticipated in these forward-looking statements as a result of uncertainties, including risks relating to demand, pricing, government regulation, payments and reimbursements, dependence upon contracts and pathologists, the market for pathology services, competition, and other factors identified in AmeriPath's filings with the Securities and Exchange Commission, including the Company's Prospectus dated October 21, 1997.